+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Parkinson's Disease Therapeutics Market by Drug Class Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase Inhibitors, and Others, by Route of Administration, and by Distribution Channel

  • ID: 4853490
  • Report
  • May 2019
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers a forecast and an analysis of the Parkinson’s disease therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the Parkinson’s disease therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Parkinson’s disease therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the Parkinson’s disease therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the Parkinson’s disease therapeutics market by segmenting it based on drug class, route of administration, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries.

Some players of the global Parkinson’s disease therapeutics market are Teva Pharmaceutical Industries, STADA Arzneimittel, Impax Laboratories, Novartis, F. Hoffmann-La Roche, Merck & Co., UCB Inc., GlaxoSmithKline, AbbVie, and Valeant Pharmaceuticals International.

This report segments the global Parkinson’s disease therapeutics market into:

Global Parkinson’s Disease Therapeutics Market: Drug Class Analysis

  • Levodopa Combination
  • Dopamine Agonists
  • Monoamine Oxidase B (Mao-B) Inhibitors
  • Anticholinergic Drugs
  • Catechol-O-Methyltransferase (COMT) Inhibitors
  • Others

Global Parkinson’s Disease Therapeutics Market: Route of Administration Analysis

  • Oral
  • Transdermal
  • Subcutaneous
  • Intestinal Infusion

Global Parkinson’s Disease Therapeutics Market: Distribution Channel Analysis

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

Global Parkinson’s Disease Therapeutics Market: Regional Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Parkinson's disease therapeutics market, 2016-2025 (USD Billion)
    • 2.2. Global Parkinson's disease therapeutics market: Snapshot
  • Chapter 3. Parkinson's Disease Therapeutics Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Parkinson's disease therapeutics market drivers: impact analysis
      • 3.2.2. Increasing environmental factors and genetic heredity causing Parkinson's
    • 3.3. Market Restraints
      • 3.3.1. Global Parkinson's disease therapeutics market restraints: impact analysis
      • 3.3.2. Patent expiration of key branded drugs and side-effects of therapeutic drugs
    • 3.4. Opportunities
      • 3.4.1. Promising products in the pipeline
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by drug class
      • 3.6.2. Market attractiveness analysis, by route of administration
      • 3.6.3. Market attractiveness analysis, by distribution channel
      • 3.6.4. Market attractiveness analysis, by region
  • Chapter 4. Global Parkinson's Disease Therapeutics Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Parkinson's disease therapeutics market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Parkinson's Disease Therapeutics Market - Drug Class Analysis
    • 5.1. Global Parkinson's disease therapeutics market: drug class overview
      • 5.1.1. Global Parkinson's disease therapeutics market revenue share, by drug class, 2018 and 2025
    • 5.2. Levodopa Combination
      • 5.2.1. Global Parkinson's disease therapeutics market for levodopa combination, 2016-2025 (USD Billion)
    • 5.3. Dopamine Agonists
      • 5.3.1. Global Parkinson's disease therapeutics market for dopamine agonists, 2016-2025 (USD Billion)
    • 5.4. Monoamine Oxidase B (MAO-B) Inhibitors
      • 5.4.1. Global Parkinson's disease therapeutics market for monoamine oxidase B (MAO-B) Inhibitors, 2016-2025 (USD Billion)
    • 5.5. Anticholinergic Drugs
      • 5.5.1. Global Parkinson's disease therapeutics market for anticholinergic drugs, 2016-2025 (USD Billion)
    • 5.6. Catechol-O-Methyltransferase (COMT) Inhibitors
      • 5.6.1. Global Parkinson's disease therapeutics market for catechol-o-methyltransferase (COMT) inhibitors, 2016-2025 (USD Billion)
    • 5.7. Others
      • 5.7.1. Global Parkinson's disease therapeutics market for others, 2016-2025 (USD Billion)
  • Chapter 6. Global Parkinson's Disease Therapeutics Market - Route of Administration Analysis
    • 6.1. Global Parkinson's disease therapeutics market: route of administration overview
      • 6.1.1. Global Parkinson's disease therapeutics market revenue share, by route of administration, 2018 and 2025
    • 6.2. Oral
      • 6.2.1. Global Parkinson's disease therapeutics market for oral, 2016-2025 (USD Billion)
    • 6.3. Transdermal
      • 6.3.1. Global Parkinson's disease therapeutics market for independent transdermal, 2016-2025 (USD Billion)
    • 6.4. Subcutaneous
      • 6.4.1. Global Parkinson's disease therapeutics market for subcutaneous, 2016-2025 (USD Billion)
    • 6.5. Intestinal Infusion
      • 6.5.1. Global Parkinson's disease therapeutics market for intestinal infusion, 2016-2025 (USD Billion)
  • Chapter 7. Global Parkinson's Disease Therapeutics Market - Distribution Channel Analysis
    • 7.1. Global Parkinson's disease therapeutics market: distribution channel overview
      • 7.1.1. Global Parkinson's disease therapeutics market revenue share, by distribution channel, 2018 and 2025
    • 7.2. Hospital Pharmacy
      • 7.2.1. Global Parkinson's disease therapeutics market for hospital pharmacy, 2016-2025 (USD Billion)
    • 7.3. Retail Pharmacy
      • 7.3.1. Global Parkinson's disease therapeutics market for retail pharmacy, 2016-2025 (USD Billion)
    • 7.4. Online Sales
      • 7.4.1. Global Parkinson's disease therapeutics market for online sales, 2016-2025 (USD Billion)
  • Chapter 8. Global Parkinson's Disease Therapeutics Market - Regional Analysis
    • 8.1. Global Parkinson's disease therapeutics market: regional overview
      • 8.1.1. Global Parkinson's disease therapeutics market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.2.2. North America Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.2.3. North America Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.2.4.2. The U.S. Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.2.4.3. The U.S. Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.2.5. Canada
        • 8.2.5.1. Canada Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.2.5.2. Canada Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.2.5.3. Canada Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.3.2. Europe Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.3.3. Europe Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.4. UK
        • 8.3.4.1. UK Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.4.2. UK Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.4.3. UK Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.5.2. Germany Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.5.3. Germany Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.6.2. France Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.6.3. France Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.3.7.2. Rest of Europe Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.3.7.3. Rest of Europe Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.4.2. Asia Pacific Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.4.3. Asia Pacific Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.4. China
        • 8.4.4.1. China Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.4.2. China Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.4.3. China Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.5.2. Japan Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.5.3. Japan Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.6. India
        • 8.4.6.1. India Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.6.2. India Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.6.3. India Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.4.7.2. Rest of Asia Pacific Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.4.7.3. Rest of Asia Pacific Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.5.2. Latin America Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.5.3. Latin America Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.5.4.2. Brazil Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.5.4.3. Brazil Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
        • 8.5.5.2. Rest of Latin America Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
        • 8.5.5.3. Rest of Latin America Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Parkinson's disease therapeutics market revenue, by drug class, 2016-2025 (USD Billion)
      • 8.6.2. The Middle East and Africa Parkinson's disease therapeutics market revenue, by route of administration, 2016-2025 (USD Billion)
      • 8.6.3. The Middle East and Africa Parkinson's disease therapeutics market revenue, by distribution channel, 2016-2025 (USD Billion)
  • Chapter 9. Company Profile
    • 9.1. Teva Pharmaceutical
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. STADA Arzneimittel
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Impax Laboratories
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Novartis
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. F. Hoffmann-La Roche
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Merck & Co.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. UCB, Inc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. GlaxoSmithKline
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. AbbVie
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Valeant Pharmaceuticals International
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll